ACCESS Newswire

Aristotle Introduces Integrity FinAfford and Partnership With Department of Trust for Financial Risk Checks

16.1.2025 13:30:00 CET | ACCESS Newswire | Press release

Share

WASHINGTON, D.C., WASHINGTON, D.C. / ACCESS Newswire / January 16, 2025 / Aristotle Integrity, the KYC and Identity division of Aristotle, is delighted to announce its partnership with the Department of Trust to deliver affordability checks and advanced diligence technology. This partnership addresses the needs of UK-regulated online gambling companies, which must comply with stricter UKGC responsible gambling requirements effective from 28th February 2025. From this date, online gambling operators are required to perform financial risk checks when a player's net deposits exceed £150 within a 30-day period - approximately 20% of online players. Additional due diligence is also mandated for higher spending or identified risks that warrant intervention.

John Aristotle Phillips, CEO of Aristotle, commented:

"The ability to integrate such a valuable technology like the Department of Trust's will further enhance our Integrity FinAfford product. By combining Aristotle's extensive history and performance in the regulated iGaming business for KYC with the Department of Trust's award-winning financial risk and vulnerability checks into a unified service, FinAfford provides an ideal solution for operators needing a seamless way to integrate and meet the rapidly approaching compliance deadline and beyond."

DoTrust CEO Charles Cohen added:

"We are thrilled to have been selected by Aristotle to enhance FinAfford with our comprehensive range of risk assessments. Aristotle holds a leading position in the global iGaming market and enjoys a strong reputation for customer focus and innovation. Through this partnership, we will deliver our uniquely compliant, accurate, and auditable risk assessments to more operators at this critical juncture."

Integrity FinAfford, when combined with Aristotle's Integrity IDV product within the KYC process, simplifies player onboarding. FinAfford enables operators to conduct financial risk checks simultaneously, providing assessments and other key variables to operators, helping them determine deposit thresholds per player and reduce exposure to social responsibility challenges in the future. UK iGaming operators now have access to a combined product that facilitates setting initial player deposit limits and, as the player's activity increases, seamlessly meets higher diligence requirements.

Aristotle plans to extend its Integrity FinAfford product to Brazil, anticipating similar responsible iGaming affordability checks in this newly regulated market. Phillips added:

"Integrity has always been at the forefront of regulated iGaming markets, and supporting our partners in meeting their regulatory obligations is central to our technological development. As iGaming markets mature, regulatory bodies assess the political and social landscapes and adapt their requirements. We anticipate responsible gaming provisions becoming an integral part of regulations, and FinAfford is designed to help our partners meet these needs. In addition to Brazil, we are exploring the expansion of Integrity FinAfford's coverage to the United States."

About Aristotle Integrity Aristotle Integrity is a leader in identity and KYC solutions for regulated markets, providing innovative tools to ensure compliance and streamline operations. For more information, visit integrity.aristotle.com

About Department of Trust The Department of Trust is an award-winning provider of financial risk and vulnerability checks, offering cutting-edge solutions for responsible gaming and compliance. Learn more at dotrust.co.uk

Media Contact: Brandi Travis
CMO, Aristotle
press@aristotle.com

###

Contact Information

Brandi Travis
CMO
brandi.travis@aristotle.com
270-704-2462

SOURCE: Aristotle



View the original press release on ACCESS Newswire

Aristotle

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

GoodData Kicks Off 2026 with MCP Server Launch and Major Enterprise Wins15.4.2026 12:00:00 CEST | Press release

Financial services wins and three platform launches signal accelerating enterprise demand for agentic analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q1 2026 results driven by the launch of its MCP Server for agentic analytics, significant new contracts in global financial services, and continued expansion into new markets. The quarter built on a record-breaking 2025, reinforcing GoodData's position as the platform enterprises trust to move AI from pilot to production. Continued growth across enterprise and financial services GoodData's commercial momentum remained strong throughout Q1, with notable wins across the enterprise and financial sectors. The company secured a new three-year contract with one of the world's largest asset managers, and a key long-term customer in global payments renewed for three years while expanding its enterprise license. "Our Q1 results demonstrate that t

GoodData Kicks Off 2026 with MCP Server Launch and Major Enterprise Wins15.4.2026 12:00:00 CEST | Press release

Financial services wins and three platform launches signal accelerating enterprise demand for agentic analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q1 2026 results driven by the launch of its MCP Server for agentic analytics, significant new contracts in global financial services, and continued expansion into new markets. The quarter built on a record-breaking 2025, reinforcing GoodData's position as the platform enterprises trust to move AI from pilot to production. Continued growth across enterprise and financial services GoodData's commercial momentum remained strong throughout Q1, with notable wins across the enterprise and financial sectors. The company secured a new three-year contract with one of the world's largest asset managers, and a key long-term customer in global payments renewed for three years while expanding its enterprise license. "Our Q1 results demonstrate that t

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release

Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release

Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a

IDC Defines the Next Era of Technology Intelligence with the Introduction of IDC Quanta(TM) at Directions 20268.4.2026 17:15:00 CEST | Press release

New AI-powered platform establishes an embedded intelligence layer for the AI economy, delivering decision-grade insight BOSTON, MA / ACCESS Newswire / April 8, 2026 / IDC today opened IDC Directions 2026, its flagship client event, bringing together technology leaders, analysts, and industry experts to examine the forces reshaping the global technology market and to introduce a major evolution in how technology intelligence is delivered. At the center of this year's event is IDC Quanta™, a new AI-powered platform that establishes what IDC defines as the technology intelligence layer for the AI economy. As artificial intelligence accelerates the pace of business and compresses decision cycles, IDC is redefining its role from a destination for research and data to an embedded intelligence capability that delivers trusted insight directly into the workflows where decisions are made. "AI is compressing time across the entire technology market, and that breaks the traditional research mode

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye